Service de medicine nucleaire
Service de medicine nucleaire
Tapsoba T.L.,Service de medicine nucleaire |
Diendere G.G.W.,Service de medicine nucleaire |
Sanon H.,Service de medicine nucleaire |
Ouattara T.F.,Service de medicine nucleaire |
And 4 more authors.
Medecine Nucleaire | Year: 2013
Bone scintigraphy 99mTc-MDP is a test carried out at the university hospital CHUYO since January 2012. After a few months of operation, our aim is to study the contribution of bone scintigraphy in the staging of cancer at the university hospital Yalgado Ouedraogo. This is a retrospective descriptive study conducted from January 2012 to March 2013. Seventy (70) patients were included in the study, all with a known or unknown primary tumor, and who have received a bone scan in search of bone metastases. Bone scintigraphy was performed using 99mTc-MDP at the late phase, an average of 3hours after injection. Of the seventy (70) patients in the study, fifty-six (56) patients or 80% of cases had a known primary tumor. Of these patients, 23 (41%) had prostate cancer and 22 or 39.3% of cases had breast cancer. Forty-four (44) patients or 78.6% of cases received a bone scan as part of the monitoring of cancer. Bone scintigraphy has revealed some suspect hyperfixations of bone metastases in 45.8% of patients. The spine, pelvis and ribs were the sites most frequently affected by metastases. Prostate and breast cancers were the most frequent. The diagnostic value of bone scintigraphy is mainly due to its high sensitivity, which enables an early diagnosis. As for further exploration, the results must be considered in the clinical context. © 2013.
Bakhsh A.,Service de medicine nucleaire |
Venel Y.,Service de medicine nucleaire |
Courtehoux M.,Service de medicine nucleaire |
Maia S.,Service de medicine nucleaire |
And 3 more authors.
Medecine Nucleaire | Year: 2016
Objective To define an optimal acquisition protocol for 18-fluorocholine (18-FCH) PET/CT in prostate cancer (PCa), due to lack of standard guidelines from the nuclear medicine associations. Materials and methods Twenty-four PCa patients were included and have had an 18-FCH three phase PET/CT: dynamic pelvic study during the first 10 minutes post-tracer injection (PI), static base of skull–mid thigh at 20 and 60 minutes PI. A quantitative analysis of tracer activity was performed on target tissue and healthy ones at 20 and 60 minutes by drawing regions of interest and measuring the SUVmax. A statistical analysis was performed on the SUVmax values of the lesions obtained at 20 and 60 minutes PI in order to find a difference between the results and also between the lesions and healthy tissue. Results Our study showed no significant difference in the SUVmax values measured at target tissue between 20 and 60 minutes (P = 0.98). However, there is a significant difference between target and healthy tissue (Pprostate = 0.006 at 20 and 60 minutes, Plymph node = 0.016 at 20 minutes 0.0047 at 60 minutes). Our sample group was too small to obtain a statistical difference between healthy bone and target lesion. Conclusion Our study showed no significant differences between the results of 18-FCH PET/CT obtained at 20 and 60 minutes PI in PCa. So we propose a pelvic dynamic acquisition during the first 10 minutes PI, then an acquisition PET/CT from the cranial vault-mid thigh at 20 minutes PI. © 2016 Elsevier Masson SAS